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INTRODUCTION 
Thyroid disorder is one of the most common disease among all  
endocrine disorders. Measurement of Serum Thyroid Stimulating Hormone 
(TSH) concentrations are made in most of the laboratories, mainly to screen for 
primary hypothyroidism. Prevalence of hypothyroidism in the general 
population ranges from 3.8% - 4.6%. 
1
  Another epidemiology study in the 
Indian population suggested the overall prevalence of hypothyroidism to be 
10.95%. 
2
 A follow up survey to determine the incidence and natural history 
showed an annual incidence of hypothyroidism of 4.1 per 1000 survivors per 
year in women and 0.6 per 1000 survivors per year in men. 
3
. Studies have 
suggested that subclinical hypothyroidism has a prevalence of 4 to 10% in the 
general population and the prevalence is found to increase with age and also 
females more than 45yrs of age have more preponderance. 
50
.   It has been 
estimated that about 42 million people in India suffer from thyroid diseases. 
4
 
         Measurement of Serum Thyroid Stimulating Hormone (TSH) levels in the 
blood  sample is the initial best way for the testing of thyroid function. Thus 
sensitivity and  specificity of the thyroid function test is very important. 
Especially for detecting and  treating thyroid diseases, in patients with 
nonspecific and vague clinical symptoms, the diagnosis and management 
mainly depends on TSH levels. TSH being an essential  laboratory parameter, 
11 
 
its reliability is very important. There are also a number of  incidences where 
TSH values may not correlate with the patient ‘s clinical features. Not  all high 
TSH values are due to true elevation of thyroid stimulating hormone, there are  
number of causes of interference in thyroid hormone assay. The potential 
interferences  are cross reactivity, drugs, antibodies and macrocomplexes.  
Cross reactivity occurs when some endogenous molecules have a similar 
structure to the measuring analyte, for example TSH and HCG carries an 
analogue alpha chain that  can cause interference. With development of specific 
monoclonal antibodies cross reactivity has been almost eliminated from modern 
assays. Other causes of interference include drugs, antibodies and 
macrocomplexes .
5
 . Antibodies which may cause  interference in thyroid assay 
includes HAMA [human anti mouse antibodies],  heterophile antibody and 
rheumatoid factors. However these interferences can be minimised by treating 
the sample with blocking agents and performing the assay. The occurrence of 
macrocomplexes is well known with hormones and enzymes like prolactin 
(macroprolactin), creatine kinase (macrocreatine kinase) and amylase (macro 
amylase). Recently, cases have been reported with unexplained high TSH 
values, but clinically euthyroid and they were found to have macro TSH. 
Prevalence of macro TSH varies from 0.6 to 0.79% 
5
. The prevalence of macro-
TSH in patients with latent hypothyroidism is 1.62% 
6
. 
Macro hormones are high molecular weight hormones which are 
conjugated with immunoglobulin, most often occurs as a complex of TSH – 
12 
 
immunoglobulin G.  The molecular weight of TSH is approximately 30 kDa 
and it is easily filtered by kidney,  but on combining with an immunoglobulin 
(IgG) molecule, the molecular weight of  this large complex increases to 
approximately to 200 kDa, which bypasses its filtration  by the kidney and leads 
to accumulation of macroTSH in the serum. 
8
. This can cause misleading high 
values. These macro hormones are biologically inert and lack hormonal activity 
so, it is assumed that practically no treatment is needed 
7
. But the  patients may 
be subjected to thyroid replacement therapy due to spurious elevation of serum 
TSH values and can even end up in thyrotoxic state. 
Macro TSH leads to artefactual TSH elevation which does not correlate 
clinically and can cause unnecessary repetition of clinical investigation and 
management 
5
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REVIEW OF LITERATURE 
THYROID GLAND – An overview  
ANATOMY  
The word ‘thyroid’ was named by WHARTON which means oblong 
shield 
12
.  The  thyroid gland is in the form of butterfly-shape which is situated 
in front of the neck  just above trachea 
13
. The thyroid gland has two lobes 
connected by the isthmus and  a fully formed thyroid gland weighs around 15 to 
20 g. Thyroid gland is lined by the  thyroid follicle which acts as a secretory 
unit. The height of thyroid follicle depicts  functional activity of thyroid gland. 
Lacunae which is in the center of follicle lined by  the apex of follicular cells is 
composed of colloid. The composition  of colloid is thyroglobulin (Tg) and 
iodinated thyroalbumin. The important reactions like iodination  and the initial 
phase of hormone secretion, colloid resorption, are believed to take place  near 
the surface of the epithelial cells which plays an important role in of thyroid  
hormone synthesis. The thyroid gland also has parafollicular or C cells which 
produce  the polypeptide hormone calcitonin. These cells are located within the 
follicular  basement lamina or found in the interfollicular spaces. Vascular 
supply to thyroid  gland is provided by Superior and inferior thyroid arteries 
and veins. 
14
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FIG 1 : SHOWING FUNCTIONS OF THYROID HORMONES 
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FUNCTIONS OF THYROID HORMONE: 
Some of the important biological effect of thyroid hormone are : 
 it controls basal metabolic rate 
 required for normal growth and neural development  
 increases adrenergic activity thus increasing heart rate and myocardial 
contraction 
 helps in carbohydrate metabolism and protein synthesis 
 increase the synthesis and degradation of cholesterol and triglycerides  
 enhances calcium and phosphorus metabolism  
 increases the sensitivity of adrenergic receptors to catecholamines 
PHYSIOLOGY 
 Hypothalamic - pituitary -thyroid axis is formed well by 20 weeks of 
fetal life. The thyrotropin releasing hormone [TRH] from hypothalamus 
stimulates Thyroid  stimulating hormone [TSH, thyrotropin] synthesis. 
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FIG 2: STRUCTURE OF of hTSH . The α-subunit is shown in grey line, and 
the β-subunit chain is depicted in black line. . The peripheral β-hairpin loops 
are as: αL1, αL3 in the α-subunit; βL1, βL3 in the β-subunit.  
TSH is a glycoprotein secreted from anterior pituitary which in turn stimulates 
the synthesis of thyroid hormones 
15
. TSH is a heterodimeric cystine knot 
glycoproteins   consisting of two noncovalently linked alpha and beta subunits. 
Alpha subunit is encoded by gene on chromosome 6 whereas beta subunit is 
encoded by gene on chromosome 1. Alpha subunit of TSH shares a common 
structure with other hormones like lutenising hormone [LH] and follicle 
stimulating hormone [FSH], whereas the beta subunit is unique 
16
. The pituitary 
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gland is made up of three lobes: the anterior, intermediate, and posterior lobes. 
The anterior lobe of pituitary has pars tuberalis  [PT], pars distalis [PD] and 
pars intermedia. The pars distalis of pituitary gland is responsible for synthesis 
and secretion of TSH -PD which are positively regulated by hypothalamic 
thyrotropin – releasing hormone [TRH].  Thyroid stimulating hormones 
secreted from pars distalis of the pituitary 
17
 act predominantly through thyroid 
hormone receptor (TRβ2) on thyrocytes to synthesis and release thyroid 
hormones[TH]. The circulating thyroid hormone formed inturn inhibits PD-
TSH by negative feedback mechanism 
15
. 
 
 
FIG 3 : DIAGRAM SHOWING PARTS OF PITUITARY GLAND. 
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PT -TSH regulation 
PT-TSH is independent of TRH regulation 
TSH secreted from pars tuberalis of the pituitary gland plays an 
important role in regulating seaonality.
18, 19, 20
.  The changes in day length 
regulates some of our physiological activities, like reproduction and migration. 
Long-day (LD) stimulus induces the production of PT-TSH. This PT- TSH   
acts on TSHR found in ependymal cells of mediobasal hypothalamus (MBH), 
which in turn causes expression of  Dio2 gene. Dio2 gene encodes for type 2 
deiodinase. The action of type 2 deiodinase  enzyme is that it activates TH and 
converts the  thyroxine (T4) to bioactive  triiodothyronine (T3) within the MBH, 
which serves as a key factor for regulation of seasonality. 
21
 
Tissue specific glycosylation imparts specificity to TSH 
Thus in contrast to PD-TSH, the PT-TSH does not take part in regulation 
of TSH ,the reason behind this is that PT cells lack TRH receptor (TRHR) 
22
. 
But the PT is found to have melatonin receptors [MTI] which is not found in 
PD 
23
. Eyes receive photoperiodic information and transmits it to pineal gland 
24
. Pineal gland plays a major role in secretion melatonin in the night which acts 
as a signal of night length 
24
. Thus PT -TSH is influenced by melatonin and 
photoperiodic informations plays an important part in regulation of TSH in the 
PT 
25
.   
20 
 
 
 
. 
FIG 4: Action of PT TSH. Photoperiodic information is encoded by the 
nocturnal melatonin signal generating signals in response to (long) summer 
day lengths. The prim site of action is the pituitary pars tuberalis. LD 
activates TSHβ leading to  increase in deiodinase 2 activity in adjacent 
ependymal cells (tanycytes), which has  TSH receptor. Thus LD leads to 
increase of T3, via conversion from T4 to T3 switch now acts on  
remodelling of reproductive and metabolic processes.  TSH-expressing cells 
21 
 
of the PT does not have  TRH receptor, therefore cannot be regulated by a  
hypothalamic peptide (TRH).  
 PT-TSH shows less bioactivity : 
 PT thyrotrophs distinct from PD thyrotrophs 
PT thyrotrophs were distinct from PD thyrotrophs which was revealed 
by a series of  electron microscopic analyses 
26, 27
 and the TSH concentration 
inside PD was ~10,000 times greater than that of PT.  PD thyrotrophs have 
large amount of dense secretory granules, when compared with PT thyrotrophs 
which has only a lesser amount of granules. PT thyrotrophs has a well-formed 
Golgi apparatus with numerous  microvesicles, and lesser amount of secretory 
granules, that mimics PD thyrotrophs of thyroidectomized rat 
28, 29
. The 
different regulatory mechanisms of PD-TSH and PT-TSH was taken into 
account for controlling source of TSH in the circulation. Thus, PT thyrotrophs 
causes release TSH 
30, 31
 and because serum T4 concentration has to increase in 
response to TSH , serum T4 level was measured. But in contrast serum              
T4 levels was not affected by differences in serum TSH, suggesting that PT-
TSH has little bioactivity in the circulation.  
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 Differential glycosylation of the two TSHs:The molecular weights of 
PT-TSH was around ~40 kDa and that of PD-TSH was ~37 kDa 
15
. 
Differential glycosylation of TSH was one the main reason for the 
difference in their molecular weight. In PD TSH, glycans were mainly 
biantennary and sulfated complexes 
32
. Though PT-TSH shares few of 
these biantennary N-glycans, tetra-antennary and tri-antennary multi-
branched N-glycans linked together with sialic acid were also found in 
the PT. Because negatively charged sulfates affect the intensity of the 
positive-ion mass, spectrograph 
32
 quantitation of N-glycan is relatively 
difficult.  The tissue-specific expression of glycosyltransferases causes 
the difference in oligosaccharides between PD- and PT-TSH. This tissue 
specific glycosylation of PT is the cause of the low bioactivity of PT-
TSH in the peripheral circulation [15]. This TSH can bind to serum 
immunoglobulin (IgG) to form a higher molecular-weight complex 
known as “macro-TSH” which has little bioactivity in humans and 
rats [33].  
      The molecular weight of TSH is approximately 30 kDa, but when it 
combines with immunoglobulin (IgG) it forms a high molecular-weight 
complex of approximately 200 kDa, which bypasses its filtration  by the 
kidney and leads to accumulation of macroTSH in the serum. 
8
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FIG 5: .STRUCTURE OF PD - TSH AND PT- TSH. 
PD TSH , glycans were mainly biantennary and sulfated complexes 
PT-TSH. tetra-antennary and tri-antennary multi-branched N-
glycans      linked together with sialic acid   
HYPOTHYROIDISM   
Hypothyroidism  is a very common  thyroid disorder due to thyroid hormone 
deficiency, which can be easily diagnosed and managed, but can be potentially 
fatal when left  untreated. It is found in 2% to 15% of the population among 
which women are  more frequently affected than men. The statistical reference 
ranges of the relevant biochemical parameters plays a crucial role in defining 
hypothyroidism.  
Based on TSH and FT4 values hypothyroidism is classified as 
24 
 
 Primary hypothyroidism 
 Central hypothyroidism 
PRIMARY HYPOTHYROIDISM 
In primary hypothyroidism, TSH is raised with low levels of free 
thyroxine (FT4) which is mainly due to primary thyroid gland failure. The 
primary hypothyroid may be caused due to endogenous and exogenous factors. 
Endogenous causes are autoimmune thyroiditis, inborn errors and 
developmental anomalies. Exogenous factors causing hypothyroidism are, 
either iodine deficiency or excess, drugs,  goitrogens, post surgical or following 
radioactive iodine treatment.  In primary hypothyroidism the feedback 
mechanism causes compensatory thyroid enlargement (goiter) through the 
hypersecretion of thyrotropin-releasing hormone (TRH) and TSH due to 
decreased thyroid hormones. Primary nongoitrous hypothyroidism is due to loss 
or atrophy of thyroid tissue, which results in decreased production of thyroid 
hormones inspite of maximum stimulation by TSH. Hashimoto thyroiditis is the 
most common  type of primary hypothyroidism in developed countries where 
iodine intake is sufficient, Whereas in under developed and developing 
countries, the iodine deficiency is the common cause of goitre in 
hypothyroidism. The commonest  cause of nongoitrous hypothyroidism is after 
thyroidectomy or after radio-ablation of the thyroid gland in case of Graves 
25 
 
disease. Primary hypothyroidism is most commonly associated with circulating 
antithyroid antibodies which can be found in coexistence with other diseases in  
which autoantibodies are present. In addition, primary hypothyroidism can be 
one of  the manifestation of an autoimmune syndromes. Thus impaired T3, and 
T4, leading to increased secretion of pituitary TSH cause remarkable increase 
in serum TSH concentrations. Hence elevated concentration of TSH is an 
important laboratory finding in the early detection of thyroid disorders. 
CENTRAL HYPOTHYROIDISM 
Central hypothyroidism is due to pituitary disorders which can be caused 
by tumours, malformation or post infection. Central hypothyroidism  can be 
secondary hypothyroidism due to TSH deficiency or tertiary hypothyroidism 
due to hypothalamic disorder from thyroid releasing hormone deficiency . 
Central hypothyroidism occurs either due to hypothalamic or pituitary diseases 
that can produce a deficiency in TRH, TSH, or both. Isolated TSH deficiency is 
very rare, and most often patients with secondary hypothyroidism have 
associated pituitary hormone deficiencies as well as panhypopituitarism. In 
secondary hypothyroidism, the serum concentration of thyroid hormone is low, 
and TSH concentrations is either low or within normal range. When T4 and 
TSH concentrations are both low, a TRH test measurement can help in the 
diagnosis. In patients with destructive lesions of the pituitary gland that result 
in TSH deficiency, there is no response to TSH with exogenous TRH 
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administration. In patients with hypothalamic defect the peak TSH response to 
TRH can be normal, but can have a delay 45 or 60 minutes after the TRH 
administration when compared to the usual time of 20 to 30 minutes. 
SUBCLINICAL HYPOTHYROIDISM 
Subclinical hypothyroidism  has serum thyroid-stimulating hormone 
(TSH) level above the upper limit of normal inspite of  normal levels of serum 
free thyroxine 
78
. 
Subclinical hypothyroidism (SCH) is diagnosed when the serum thyroid 
stimulating hormone (TSH) level is consistenly high for 6 to 12 weeks with 
FT4 concentration within normal reference range. Causes of subclinical 
hypothyroidism are recovery from non thyroidal illness, positively interfering 
antibodies , suboptimal treatment of primary hypothyroid or poor patient 
compliance with the thyroid replacement. Previous studies suggested that, 51% 
of 3775 patients with TSH 5.5–10 mIU/L were found to have TSH levels 
within the reference range when they were remeasured 5 years later 
48,49,
  
without any treatment.  Therefore routine treatment of subclinical 
hypothyroidism is still controversial.  But experts have suggested thyroid 
replacement therapy is essential for   patients with subclinical hypothyroidism 
with TSH  10 mIU/L or greater. 
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CLINICAL SYMPTOMS 
The most common symptoms in adults are tiredness, lethargy, cold 
intolerance, constipation, horseness of voice, weight gain, and dry skin. 
Sometimes the symptoms are vague and generalized that they can be missed.  
Thus statistical reference ranges of  biochemical parameters like TSH 
plays a crucial role in defining hypothyroidism. The standard treatment is 
thyroid hormone replacement therapy with levothyroxine.  
TSH MEASUREMENT. 
Serum TSH as a single hormone , is one of the most sensitive index for 
detection of thyroid abnormalities 
51
. The current standard of care has even 
more improved with upcoming of automated immunochemiluminometric assays 
for TSH which are ultrasensitive  
54
. The assay has a sensitivity of 0.004 
mIU/L. 
Measurement of TSH plays a crucial role in newborn screening, work up 
of female infertility, in monitoring thyroid replacement therapy and in 
screening adults for other thyroid diseases. 
Misleading TSH value : 
The diagnosis of TSH values can be misleading due various interfering 
factors. They can be either due to biological or technical factors . 
28 
 
Biological factors are : 
 Unstable thyroid status When the thyroid hormone replacement therapy 
is suboptimal or in case of  poor patient’s compliance there is a lag in 
resetting of pituitary TSH, during such period there is TSH instability 
which can be misleading. 
 TSH secreting tumours like adenomas 
 Central hypothyroidism 
 Hypothalamic dysfunction 
 Resistance to thyroid hormone 
Technical factors :  
There are various interferences that can contribute to errors in the 
laboratory values. The effects of interferences like lipemia, hemolysis and 
bilirubinemia are well known for all assays. Immunoassays are mainly 
subjected to antigen-antibody interactions that alter and cause interference in 
the measurement of analyte.  
Endogenous antibodies are known to bind or block the binding sites 
present on the capture and signal antibodies , which can cause falsely high 
values. Some of the endogenous antibodies are heterophile antibodies and 
rheumatoid factors. The most common autoantibodies are  
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 antibodies to thyroglobulin, 
 antibodies to microsomal thyroid peroxidase, 
 antibodies to the TSH receptor ,  
 antibodies to T4 and T3 . 
 Antibodies against TSH 
Technical factors due to endogenous antibodies are one of the most common 
causes of a false elevation TSH  
52,53
.  
Antibodies can be: 
 Antibodies against assay antibodies eg. Heterophile antibody 
 Antibodies against analyte eg: macro TSH 
 Antibodies against signal molecules eg: anti-Rhuthenium antibodies. 
Heterophile antibodies (HAbs).  
Heterophile antibodies are weak antibodies which are generally non 
specific and  directed against poorly defined antigens. Human 
anti‐ mouse monoclonal antibody (HAMA) and  rheumatoid factor ( RF 
) are two important heterophile antibodies that can cause interference in 
TSH assay. The prevalence of HAbs is  30-40 percent 
55
 and have the 
potential to interfere with methods that use immunometric assays 
(IMA)
56
.  
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  ENDOGENOUS  ANTIBODIES CAUSING INTERFERENCE 
 
 
                   
  
FIG 6 : . Falsely elevated measurements due to interference from heterophile 
antibodies. 
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FIG 7: . ENDOGENOUS  ANTIBODIES ARE PRODUCED AGAINST 
POORLY DEFINED ANTIGENS .THEY CAN CAUSE FALSE POSITIVE  
OR NEGATIVE RESULTS 
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Heterophile antibodies (HAb), which are  human poly-specific 
antibodies that targets  against animal antigens,among which  the human anti-
mouse antibodies (HAMA) is most common one 
57
.HAMA is found to occur in 
40% - 70% of patients treated with mouse monoclonal antibody and it can 
occur in 10 % of the general population.    HAb can also  target human antigens 
58
 like  rheumatoid factor (RF), an immunoglobulin which is commonly 
associated with autoimmune conditions 
59
. RF can interfere with free and total 
thyroid hormone tests, TSH 
60
 and Tg . RF factor is found to occur in 70% of 
the cases with autoimmune rheumatic disease and it can occur in 5 -  10 % of 
the general population.  Rheumatoid factor (RF) is an immunoglobulin which 
has reactivity to the Fc portion of human IgG. Some RhF species which is also 
known to  cross-react with animal immunoglobulins have the potential to act 
like heterophile antibodies. It is documented that the patients who have 
received vaccines recently , blood transfusions or those who have received 
monoclonal antibodies for treatment, as well as veterinarians and those people 
who are exposed to close contact with animals, are more prone to the 
interferences caused by HAb and HAMA 
61,62
. When HAMA interference is 
suspected, the patient's serum can be preincubated for 1 hr at room temperature 
with non immune mouse serum.  After this absorption procedure, the assay can 
be carried out, to eliminate the interference. 
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                                FIG 8: .    HAMA interference in TSH assay. 
Commercial HAMA blocking reagents are available to counteract 
heterophile antibody interferences, as well as heterophilic blocking tubes, 
heterophile‐ blocking  reagents, and non‐ specific antibody‐ blocking tubes are 
also available.  
34 
 
 
FIG 9: . INTERFERENCE OF HETEROPHILE ANTIBODY, SHOWS 
FALSE POSITIVE  RESULTS  IN SANDWICH ASSAY. 
Anti-Reagent Antibody : 
Some patients develop antibodies that are targeted against test reagents 
like Rhuthenium that cause interference with TSH .  Anti rhuthenium 
antibodies is known to occur in areas of textile industries where rhuthenium 
was used for dying process of the cloth. It should also be considered that the 
anti-Rhuthenium antibodies of different patients may differ with each analyte to 
different degrees  
63,64
. 
Antibodies against  Streptavidin-Biotin: 
 Interferences also occur from antibodies targeting against either 
Streptavidin 
65
 or biotin reagents 
66
. Reports have suggested that patients with 
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high dose of biotin ingestion are known to produce interference in TSH 
assay.
67,68
. 
 
 
                                   FIG 10 : .   ENDOGENOUS ANTIBODIES 
TSH Variants. 
TSH variants is one of the rare cause of interference 
69
. Nine different 
types of TSH beta variants have been found  . 
70
. These mutant TSH can exhibit 
altered immunoactivity that can be detected by few of TSH assay methods but 
not by others 
69
. The bioactivity of the TSH mutants shows a range of 
bioactivity that varies from  normal to bio-inert, this results in discordances 
between the TSH value and clinical status of the patient 
69
 and also discordance 
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between TSH/FT4 values 
70
. These TSH genetic variants play a major role in 
occurence of congenital hypothyroidism 
71
. 
MACRO TSH. 
Macro TSH is one of the reason for misleading high TSH values . The 
prevalence of macro TSH is approximately 0.6 percent, but can be  as high as 
~1.6 percent in patients with subclinical hypothyroidism.  
 MACRO TSH – AN OVERVIEW 
 PT TSH which has tetra-antennary, tri-antennary multi-branched N-
glycans linked with sialic acid which can conjugate with immunoglobulin, to 
form a complex of TSH – immunoglobulin G 15.  Macro TSH is found to 
complex with immunoglobulin G molecules that are found to occur as naturally 
occurring  antibodies [NABs], in contrast to the antibodies induced by 
exogenous antigen 
34
. Ig M is the primary immunoglobulin which produces 
NABs but Ig G is also known to produce NABs 
35
.PT TSH formed macro TSH 
mainly binds with Ig G 2b class of immunoglobulin 
15
. TSH is also know to 
form complexes with albumin 
15
. 
Macro TSH is found to have: 
 High molecular weight. 
 High stability. 
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 Long half – life 
 Low bioactivity. 
 
 
 FIG 11: . REGULATION OF TSH , FORMATION OF IgG – TSH 
COMPLEX   TSH is a hormone secreted by the pars distalis (PD-TSH) 
that stimulates the thyroid gland to synthesize and secrete thyroid 
hormones, which regulate growth and metabolism in the body. 
Hormones affect the target organ through circulation in the 
bloodstream.  PD-TSH is regulated by the thyrotropin-releasing hormone 
(TRH) secreted by the hypothalamus, whereas PT-TSH was not 
controlled by TRH but is being controlled by a hormone called 
38 
 
melatonin, which is a hormone secreted by the pineal gland during the 
night. 
       PT TSH which has a molecular weight of around ~40 kDa can conjugate 
with immunoglobulin G molecules to form a large complex of approximately 
200 kda . This large molecular weight complex is not filtered by kidney which 
causes accumulation of macro TSH.  The complex of TSH Ig - G is biologically 
inert but the immmunoreactive  property is intact so it can be measurable which 
can give a false elevation of TSH values without the patient being 
symptomatic
8
. 
The TSH Ig - G complex is found to be very stable and the PT TSH 
binds with the IgG for a longer time in the circulation. Acidification of macro 
TSH below pH 3 has been known to dissociate the macro-TSH complex in 
humans 
36,37
. But in contrast acidification of the stable mouse IgG-TSH 
complex does not dissociate the IgG-TSH complex.
15
 . 
Glycosylation plays a major role in contributing to the half-life of 
circulating glycoprotein 
38,39.
 TSH with shorter half-life (~0.5–1 h)  have a 
faster hepatic clearance. Hepatic receptors are found to interact with sulfated 
TSH, which causes pulsatile secretion of the TSH level in serum.
38,39,40
. For 
example, even though both LH and FSH shows regulation by pulsatile GnRH 
secretion, it is only LH that shows episodic variation. The reason behind this is 
39 
 
FSH has sialylated  N-glycan and lacks the sulfate modification, which results 
in a long half-life of ~17 h 
41
. Likewise, sialylated TSH is excluded from 
specific receptor-mediated clearance from the liver 
 40
. Therefore PT-TSH, 
which has multi-antennary sialylated N-glycans has a longer half-life than PD-
TSH which is one of the main reason for the longer half life of macro  TSH.  It 
was found that rodents and patients  with hypothalamic hypothyroidism shows 
increased levels  of circulating TSH with altered oligosaccharides 
42,43
.  
Hypothalamic hypothyroidism can cause the appearance of multi-
antennary N-glycans in circulating TSH 
44
. In thyroidectomized or thyroid 
tumor-induced hypothyroid mice sialylation and multi-antennary glycans were 
found to be increased, and sulfation to be reduced in circulating TSH 
45,46.
 The 
gene encoding for α2–3 sialyltransferase also plays an important role in 
increasing sialylation of TSH during hypothyroidism 
47
. 
VARIOUS METHODS FOR CONFIRMING INTERFERENCES ARE: 
 The assay can be repeated  with an alternative immunoassay 
platform, preferably using assay antibodies from a different 
species 
 Sample treatment with polyethylene glycol. 
 Sample treatment with protein G or A . 
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 Serial dilution of the samples showing  non linearity indicates assay 
interference 
PEG PRECIPITATION TEST 
PEG is polyethylene glycol which is water soluble nonionic synthetic 
polymer with an empirical formula HOCH2(CH2OCH2)mCH2OH . This was 
first introduced by polson et al in 1964 for precipitating proteins
72
.PEG 
precipitation is a very simple and cost effective method for screening antigen 
antibody interference that can be routinely be used in laboratories . PEG 
precipitates  immunoglobulins G, A and M. This method can be used as a 
simple screening test for patients suspected to have macro TSH . 
 PROPERTIES OF POLETHYLENE GLYCOL[PEG]. 
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MECHANISH OF ACTION OF PEG 
There is a positive perturbations of the chemical potentials of the 
proteins on adding PEG , there is an  interactions  between  PEG  and  proteins 
in aqueous  medium which is repulsive in nature  and  this repulsion  becomes  
stronger as the molecular size of PEG increases 
74
. Such an unfavourable  
interaction  can  be relieved by the formation of interprotein contacts  which 
can reduce the  surface area of protein that are exposed to the solvent and thus 
can reduce the interactions.  This can be achieved by either protein self 
association or   precipitation  
73.
  
POLYMER EFFECT 
Steric exclusion explains effect of polymers on protein solubility. 
 
                                              
•  -   Assuming total volume of solvent occupied by polymer and 
protein  
 
•  – volume occupied by polymer ( excluded volume not 
occupied by protein) 
 
• – volume occupied by protein 
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Increased Ve caused by increase in number or size polymer will decrease 
V ´and effective increase in concentration of protein molecule. Probability of 
collision and self association increased and large insoluble aggregates formed.  
PEG is used for separation of free hormones from those bound to 
antibodies  thus, helping as a screening tool for detecting macro TSH.   Samples 
with a recovery less than 25% using PEG precipitation method are considered 
to have antigen antibody interferences . 
PROTEIN G ADDITION TEST 
Samples with recovery less than 25% are further subjected to protein G 
addition test. Protein G agarose gel absorbs only IgG complexed form of TSH, 
so  removes most of the TSH  which exist in the form of macro TSH which is   
mostly immunoglobulin G complexed form of TSH 
 So this study is aimed to evaluate the possibility of macroTSH as an 
interference in the measurement and interpretation of TSH which may cause a 
false elevation of TSH values 
43 
 
 
FIG 12: . Adding PEG to the serum of a subject with Macro-TSH (A1) causes 
the precipitation of Macro-TSH complexes, while unbound enzymes stay in 
supernatant (A2). The supernatant measured for TSH values in ECLIA. 
.  
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AIM AND OBJECTIVES 
AIM: 
 To evaluate the interference of immunoglobin G complexed form of 
thyroid stimulating hormone [ macro TSH] in TSH assays. 
OBJECTIVES: 
 TSH more than 10 µIU /mL and FT4 within normal range [0.8 -
2.7ng/dl], are evaluated for analyte –antibody interference by PEG 
precipitation method. 
 Samples are evaluated to confirm the presence of IgG complexed -TSH 
by protein G addition test. 
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MATERIALS AND METHODS 
  This study was conducted in  government Stanley medical college 
hospital to evaluate  immunoglobulin G complexed form of thyroid stimulating 
hormone [macro TSH] as interference in TSH assay. 
 
STUDY CENTRE : 
  Government Stanley medical college hospital , Chennai -1 
DURATION OF STUDY : 
         6 months (January 2017 to June 2017) 
STUDY DESIGN: 
        Cross sectional study 
INCLUSION CRITERIA: 
Patients with TSH more than 10 mU/L and Free T4 within normal limits 
[0.8 -2.7ng/dl]     
EXCLUSION CRITERIA: 
Known case of rheumatoid arthritis, chronic infection ,multiple myeloma 
and other malignancies. 
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SAMPLE SIZE 
200. 
STUDY PROCEDURE 
 samples from patients subjected to routine analysis of thyroid function 
were scrutinised for TSH. 
 Patients with TSH more than 10 mU/L and Free T4 within normal limits 
[0.8 -2.7ng/dl] were selected . 
 Informed consent was obtained from 200 patients. 
 Two aliquots of the each serum sample were taken. 
 One aliquot of the patient ‘s serum was subjected to PEG precipitation 
test and other aliquot for protein G addition test. 
 Samples which had > 25% recovery was treated as true TSH elevation 
which had no significant interference 
 Samples which had a recovery of < 25% by PEG precipitation test  were  
further subjected to protein G addition test. 
 Samples that showed remarkable decrease in TSH recovery after protein  
G addition test  suggested immunoglobulin G complex form of TSH. 
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METHOD 
Sample collection and  preparation 
               After getting informed consent from the patient, blood sample were 
collected under strict aseptic precautions in plain red topped venipuncture tubes 
without any additives or gel barrier. Allow the blood to clot. After 
centrifugation at 2000 -2500 rpm for 15 min, serum samples were separated 
immediately from the cells and analysed for TSH . 
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DETERMINATION OF SERUM TSH  
REQUIREMENTS : 
 EQUIPMENT 
 Cobas e 411/601 Analyzer 
 Centrifuge 
 vortex mixer. 
METHOD 
Electro-chemiluminescence immunoassay (ECLIA) for in vitro 
quantitative determination of  free thyroxine, and thyroid stimulating hormone  
in human serum were performed using Automated Cobas e411 Immunoassay 
Analyzers based on electrochemiluminescent technology using ruthenium 
complex and the measuring cell. 
‘Electro’ means electrical stimulation ‘chemi ‘ refers to chemical 
reaction and luminescence indicate production of light.  
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FIG 13: COBAS e 411 - ANALYSER 
PRINCIPLE 
 The biotinylated monoclonal antibody, antigen of interest, and  
monclonal antibody labeled with ruthenium complex form a sandwich 
complex 
 After adding streptavidin-coated microparticles this complex binds to 
solid phase by interacting of biotin and streptavidin. 
 Microparticles are magnetically captured onto the surface of the 
electrode 
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 . Application of a voltage to the electrode induces chemiluminescent 
emission which can be detected by a photomultiplier. 
 
 TEST PROCEDURE TSH IN ECLIA 
Sandwich principle. Total duration of assay: 18 minutes. 
 1. First  incubation:[ 9 mins] 
 50 uL of sample reacts with first biotinylated monoclonal TSH-specific 
antibody and then with  second antibody monoclonal TSH-specific antibody 
labelled with a ruthenium complex. The two antibodies form a sandwich 
complex with the antigen or analyte of interest. 
 
  FIG 14:  FIRST INCUBATION 
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2. Second incubation:[ 9 mins] 
 After addition of streptavidin-coated microparticles, the streptavidin forms a 
strong bond with biotin .  
               
                       FIG 15:    The sandwich complex formed . 
3.      This complete immunoassay complex is now transferred to measuring 
cell. The magnet present here attracts the paramagnetic beads , thus 
binding the complex  to the surface of the measuring cell.  
4.  Now the procell applied ,which separates the particles bound to 
immunocomplex from the free particles. The procell also provides 
tripropylamine[TPA] which is essential for the electrochemi -
luminescence [ECL] reaction to take place. 
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 5.  Electrodes present provides voltage which triggers the ECL reaction . 
Ruthenium and TPA gets excited.TPA serves as reductant. TPA enable 
ruthenium to reduce to its base state with release of light. 
6.  This cycle of electrochemiluminescence repeats as long as voltage is 
applied ,this  results in amplification of light signals. The emitted light is 
detected by photomultiplier. The signal detected is directly proportional 
solution is to the concentration of the target analyte. 
 
 
  
FIG 16: THE MAGNET  ATTRACTS THE PARAMAGNETIC BEADS 
THUS BINDING THE COMPLEX. 
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FIG 17 : TPA ENABLE RUTHENIUM TO REDUCE TO ITS BASE 
STATE WITH RELEASE OF LIGHT. 
7. Results are determined with the help of a calibration curve which is 
instrument- specifically generated by 2- point calibration and a master curve 
provided by  the reagent barcode. 
REAGENT 
TSH Elecsys from Roche Diagnostics  
STORAGE AND STABILITY 
Store at 2-8 °C.  Do not freeze. 
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 MEASURING RANGE 
0.005-100 µIU/mL .  
Values below the lower detection limit are reported as < 0.005 µIU/mL.  
Values above the measuring range are reported as > 100 µIU/mL (or up to 
1000 µIU/mL for 10-fold diluted samples) 
 Functional sensitivity -  0.014 µIU/mL 
  
FIG 18: Ru(bpy)3
2+ 
COMPLEX – TPA ( TRIPROPYLAMINE ) FORMS A 
REDOX COUPLE EMITTING LIGHT SIGNALS  
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FREE T4  ASSAY 
  Principle – Competitive assay 
 Total duration of assay: 18 minutes. 
 • 1st incubation: 15 µL of sample and a T4-specific antibody labelled with a 
ruthenium complex.[9 min] 
 • 2nd incubation: After addition of biotinylated T4 and streptavidin-coated 
microparticles, the still free binding sites of the labelled antibody become 
occupied, with formation of an antibody-hapten complex. The entire complex 
becomes bound to the solid phase via interaction of biotin and streptavidin.[9 
min]  
• The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the electrode. 
Unbound substances are then removed with Procell. Application of a voltage to 
the electrode then induces chemiluminescent emission which is measured by a 
photomultiplier. 
 • Results are determined via a calibration curve which is instrument-
specifically generated by 2point calibration and a master curve provided via the 
reagent barcode.  
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 REAGENT  
  Free T4  from Roche Diagnostics  
STORAGE AND STABILITY 
Stability  
Unopened at 2 to 8 °C – upto stated expiry date 
After opening at 2 to 8 °C – 12 weeks 
On the analyser – 8 weeks 
Store at 2 to 8 °C 
Do not freeze. 
Store the Elecsys reagent kit upright in order to ensure complete availability of 
the microparticles during automatic mixing prior to use. 
LIMITS AND RANGES 
RANGE FREE T4 TSH 
MEASURING RANGE 0.101-7.77 ng/Dl  0.005-100.0 mlU/L 
REFERENCE RANGE 0.8 -2.7ng/dl 0.4 - 4.2 mIU/L 
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Measuring range for FT4 
0.101-7.77 ng/dL  
Values below the Limit of Quantitation are reported as < 0.101 ng/dL  
Values above the measuring range are reported as > 7.77 ng/dL . 
Functional sensitivity = 0.101 ng/dL  
 
REFERENCE RANGE: TSH   
 
  Birth to 4 days: 1 - 39 mIU/ml  
- 4.2 mIU/ml  
 
      I trimester   :  0.3 - 4.5 mIU/ml  
      II trimester    :  0.5 - 4.6 mIU/ml  
     III trimester     :  0.8 - 5.2 mIU/ml  
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CALIBRATION 
Calibration  performed once per reagent lot using fresh reagent .  Two 
set of two levels of calibrators  CAL 1 and CAL 2 are provided in separate kit 
for each analyte. 
 
 
 
  L – CALIBRATION WAS GENERATED. 
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QUALITY CONTROL MATERIAL 
QC  given 
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CENTRIFUGE MINI SPIN.[Eppendorf] 
 Mini centrifuge was used for separation of serum after PEG precipitation 
and protein G addition  test 
 the main switch is turned on and lid is opened 
 rotor was loaded symmetrically 
 for PEG precipitation test mixture was centrifuged for 5min at 13,400 
rotations per minute  
 for protein G addition  test the mixture was centrifuged at 12000 g for 
5min 
POLYETHYLENE GLYCOL[PEG] PRECIPITATION METHOD 
             TSH values of more than 10 mU/L and FT4 within normal limits are 
evaluated by PEG precipitation method. 
PRINCIPLE  
PEG precipitation method is a simple  procedure for precipitating 
immunoglobulins G, A and M from the serum. Precipitation of PEG is based on 
polymer effect and steric exclusion effect.  
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•  -   Assuming total volume of solvent occupied by polymer and 
protein  
 
•  – volume occupied by polymer( excluded volume not 
occupied by protein) 
 
• – volume occupied by protein 
 
 
                         FIG 19:    POLYETHYLENE GYCOL 6000 
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PROCEDURE 
PEG precipitation was used as a simple method of precipitating 
immunoglobulins G, A and M [5]. 
1. A 25% solution of PEG 6000 was prepared in deionised water. 
2. A 0.2mL of serum aliquot was added to 0.2mL of the 25% PEG 6000 
solution (TSH.PEG). 
3. To 0.2mL of deionized water, 0.2mL of the 25% PEG 6000 solution was 
added (TSH.H2O) as a control. 
4. The samples were vortex mixed and incubated for 10min at room 
temperature.  
5. Then the mixture was centrifuged for 5min at 13,400 rotations per 
minute.  
6. The TSH concentration of the supernatant was assayed using cobase e 
411.  
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FIG 20: PEG PRECIPITATION TEST – The supernatant and 
precipitate can be observed. 
 
8.The percentage recovery of TSH following PEG precipitation was calculated . 
     TEST    PEG      SERUM     DEIONISED 
WATER                  
CONTROL        0.2mL              _         0.2Ml 
SAMPLE        0.2mL          0.2Ml             _ 
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CALCULATION:    
                       
 
                                                                
PROTEIN G ADDITION TEST  
  The samples with recovery of less than 25 % were further treated with 
protein G addition test for confirming the presence of IgG complex TSH. 
Samples showing remarkable decrease in protein G addition test suggested 
immunoglobulin G form of TSH.
7
 
PRINCIPLE 
Protein G agarose gel absorbs Ig G complexed form of TSH. Therefore 
the macroTSH which mainly occurs in the form Ig G complexed TSH are 
absorbed by protein G addition test. 
PROCEDURE 
1. Protein G agarose was used for absorption of serum Ig G.  
2. A 0.2mL of serum aliquot was added to 0.2mL of the protein G agarose 
and incubated at 4 ºC for 3 hr. 
3. The above mixture was centrifuged at 12000 g for 5min 
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4. The supernatant was measured by elecsys for TSH value. 
5. Recovery calculated. 
6. Samples showing remarkable decrease in protein G addition test 
suggested immunoglobulin G complexed form of TSH. 
CALCULATION : 
 
. 
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STATISTICAL ANALYSIS & RESULTS 
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RESULTS 
STATISTICAL ANALYSIS AND RESULTS 
  In this study, 200 serum samples were collected with TSH value more 
than 10 µIU /mL and FT4 within normal range [0.8 -2.7ng/dl]. First aliquots of 
all 200 samples were treated with PEG and second aliquots of serum samples 
with recovery less than 25% were further subjected to protein G addition test. 
Of 200 sample 9 sample had a post PEG recovery of less than 25% that is 4.5%  
of the total sample collected. After subjecting 9 samples to protein G addition 
test 4 serum samples showed a marked decrease in recovery percentage 
suggesting 2% of samples had macro TSH . 
          Results of laboratory values obtained from PEG treated TSH were 
compared with the controls values ie ,TSH treated with deionized water and 
were  statistical analysis using excel software. Student’s paired ‘t’ test was used 
to compare the means between two variables . Pearson coefficient of 
correlation was used to estimate the degree of association between PEG 
precipitation method and protein G addition test . A p-value of  <0.05 
considered as statistically significant 
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Table-1 
TABLE SHOWING GENDER DISTRIBUTION OF SERUM SAMPLES 
COLLECTED. 
Gender  NUMBER (N) PERCENTAGE (%) 
MALE   22 11.00 
FEMALE 178 89.00 
TOTAL 200 100 
 
GRAPH 1: SHOWING AGE DISTRIBUTION OF SERUM SAMPLES 
COLLECTED 
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This graph shows that most of the TSH samples collected were between 30 to 
40 years of age. 
Table-2 
 AGE DISTRIBUTION OF PATIENTS 
AGE GROUP MALE FEMALE TOTAL 
NO % NO % NO % 
≤ 10 0 0  5   2.81   5   2.50 
11 – 20 3 13.64  4   2.25   7   3.50 
21 – 30 3 13.64 46 25.84 49 24.50 
31 – 40 5 22.73 65 36.52 70 35.00 
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41 – 50 3 13.64 38 21.35 41 20.50 
51 – 60 7 31.82 17   9.55 24 12.00 
≥ 61 1 04.55 3   1.69 4   2.00 
TOTAL 22 100 178 100 200 100 
 
Table showing age and gender distribution among the sample collected.  
 
 
 
 
Table-3 
TABLE SHOWING THE RESULT AFTER PEG PRECIPITAION TEST 
AND PROTEIN G ADDITION TEST. 
     
     VARIABLES 
       N=200 
  
RECOVERY 
PERCENTAGE 
 
NO OF 
SAMPLES 
 
PERCENTAGE 
OF  
SAMPLES  
 
 
PEG PRECIPITATION 
 
 
        >25 % 
 
     191 
 
     95.5% 
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TEST  
      < 25% 
 
        9 
 
      4.5% 
 
PROTEIN G  
ADDITION TEST 
 
 
      < 31% 
 
         4 
 
        2% 
 
This table shows that among 200 samples treated with PEG, 95.5% sample has 
a recovery of more than 25% and 4.5% of samples have a recovery of less than 
25%. After protein G addition test 2% of the sample shows results suggestive 
of macro TSH. 
 
 
 
 
 
                                                  Table-4 
 
 SCORES COMPARATIVE OF VARIABLES 
VARIABLES MALE FEMALE TOTAL 
MEAN SD MEAN SD MEAN SD 
TSH 34.40 31.41 36.95 30.91 36.67 30.90 
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FT4   0.94   0.17   0.97   0.23 0.97 0.22 
TSH .PEG 11.08 11.93 14.12 17.48 13.78 16.96 
TSH .WATER 17.66 17.81 21.02 22.25 20.65 21.79 
RECOVERY% 63.04 18.96 62.85 19.40 62.87 19.30 
 
Table showing mean and SD (standard deviation ) of variables analyzed in the 
study. 
 
 
 
                                          
 
 
 
Table-5 
PAIRED SAMPLE T-TEST (Pre Vs Post PEG treated values) 
VARIABLE 
N=200 
MEAN SD t-value p-value Significant 
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TSH .PEG 13.78 16.96 12.84 0.0001 Significant 
TSH.WATER 20.65 21.79 
                                                                       
TSH treated with deionized water [TSH .WATER]  is taken as control vs TSH 
treated with PEG and the values are compared by paired t test and p – value 
was derived. The test was significant. 
 
 
 
 
 
 
 
 
 
Graph.2 Histogram of percentage recovery of TSH after polyethylene 
glycol precipitation 
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RECOVERY PERCENTAGE AFTER PEG TREATMENT FOR 200 
SAMPLES SHOWS A MEAN OF 62.87 AND SD OF 19.3 
 
 
 
 
 
Table-6 
COMPARING RECOVERY PERCENTAGE AFTER PEG 
PRECIPITATION TEST  AND RECOVERY PERCENTAGE AFTER 
PROTEIN G ADDITION TEST 
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TSH 
 
N MEAN SD t-value p-value Significant 
PEG % 
 
9 17.09 3.90 3.19 0.01 Significant 
Ig G % 
 
9 30.67 12.18 
 
Serum sample with recovery < 25% in PEG precipitation method compared 
with recovery percentage after subjecting them to protein G addition test. The 
test was significant . 
 
 
 
 
 
 
 
GRAPH 3: COMPARING UNTREATED TSH AND PEG TREATED 
TSH > 25% RECOVERY 
78 
 
 
 
GRAPH 3 : Shows serum TSH concentrations before and after serum treatment 
with PEG in patients with true TSH elevation [ie] for recovery > 25 %.  Of 200 
samples 191 samples had PEG  recovery more than 25%. Comparing untreated 
TSH with PEG treated TSH samples there is no marked decrease in value 
showing no interference due to macro TSH. 
 
 
 
 
GRAPH 4 : COMPARING UNTREATED TSH AND POST PEG TREATED 
TSH < 25% RECOVERY 
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9 [ 4.5%] out of 200 samples showed a recovery of less than 25% with PEG. A 
drastic decrease in TSH values after PEG   treatment is noted.      
 
 
GRAPH 5 : COMPARING UNTREATED TSH AND AFTER PROTEIN G                        
ADDITION TEST . 
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GRAPH 4: Serum TSH concentrations before and after protein G addition test. 
4 [2%] out of 9 samples shows marked decrease in TSH values after the test 
showing a recovery of less than 31 % suggesting macroTSH. 
 
 
                                                      Table-6 
CORRELATION BETWEEN PEG RECOVERY AND PROTEIN G 
RECOVERY . 
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 r-value 
 
p-value Significant  
PEG RECOVERY 0.89 0.01 
 
Significant 
Vs 
PROTEIN G 
RECOVERY . 
 
 
Table 6: Explains the Pearson’s Correlation Coefficient Between Biochemical 
Parameter of PEG precipitation test and protein G addition test. It Revealed 
Positive Correlation Between both the recoveries  
 
 
 
 
 
 
GRAPH 6 : REGRESSION ANALYSIS BETWEEN PEG 
PRECIPITATION AND PROTEIN G ADDITION TEST 
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GRAPH 6: explains the correlation of recovery percentage after PEG 
precipitation  and protein G addition test . PEG has a positive correlation with 
protein G addition test as indicated by the upward slope of linear regression 
analysis and the r value is equal to 0.89. 
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DISCUSSION 
 
Endogenous antibodies are one of the commonest cause of interference 
in TSH assay. One of the study showed that out of 5130 sets of results, 28 
(0.53%) of them were analytically incorrect results 
5
. Out of which 23 patients 
had a potential adverse effect on the expense and clinical care. There are 
several causes of interference in thyroid  hormone assay, of which some of 
them have been virtually eliminated from modern assays while other causes of 
interference like drugs, antibodies and macrocomplexes still persist. The 
clinical consequence of these interferences may lead to false elevation         
improper therapeutic decision and unnecessary follow up examination.  
True hypothyroidism is characterised by presence of excess of 
monomeric form of TSH found in serum but if macroTSH is present along 
with monomeric form it can give  rise to false elevation of TSH.  In subclinical 
hypothyroidism, TSH value more than 10 µIU /mL is taken as a cut off for 
initiating thyroid replacement therapy 
48,49
. In order to avoid misdiagnosis of 
subclinical hypothyroidism the possibility of macro TSH should be considered 
in elevated TSH values 
7
 . Macro TSH which is  considered to be biologically 
inert may not require thyroid replacement therapy and the patients may be 
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subjected to unnecessary treatment which may cause mismanagement
75
. In the 
study published by Hiroyuki sakai et al 
7
 elevated thyroid-stimulating hormone 
(TSH) was also found during regular neonatal screening in a newborn with no 
clinical symptoms. Thyroid function tests were repeated and confirmed to have 
high TSH value but normal total thyroxine (T4) and triiodothyronine (T3). The 
mothers of the neonates also had elevated serum TSH with normal levels of T4 
and T3. This suggested a transmitted maternal interfering factor, and no 
treatment was started while further investigation suggested that serum from 
both the infant and the mother showed a peak TSH with molecular mass 
consistent with a TSH-IgG complex (macro-TSH) 
77
. The TSH values in the 
infant  also declined  to a normal level within 8 months in pace with a normal 
rate of elimination of maternal IgG .These cases suggests that interfering 
macro-TSH should also be considered in a euthyroid neonate with elevated 
serum TSH and normal T4 and T3 levels to avoid unnecessary treatment. 
PEG precipitation is commonly used to detect the interference of macro 
prolactin in clinics, but it is also used in cases that are suspected to have 
interference of TSH. PEG precipitation is a simple and cost effective technique 
which can be used as screening test for immunoglobulin complexed TSH [ 
macro TSH]. PEG is also known to  precipitate a portion of free analyte along 
with immunoglobulin, so it is necessary to determine an analyte and method 
specific reference range for PEG precipitation method. According to study 
conducted by Francesca Mills et al., a cut off of < 25 %  can be used as 
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recovery percentage for TSH after PEG precipitation. This cut off can be taken 
for directing the samples which may need further investigation into the 
possibility of presence of macroTSH.  PEG precipitation is relatively crude and 
subjected to certain limitation. The presence of increased globulin 
concentration may cause an increase in the amount of monomeric hormone 
precipitation with PEG. Other limitation of PEG is that it can interfere with 
some immunoassays.  
In this study 200 hypothyroid cases were analysed before and after PEG 
treatment .TSH values of PEG untreated sera ranges from 10.1 to 99.2 with 
mean 36.67 and SD of 30.90. After the 200 serum were treated with PEG, the 
TSH was reanalysed which showed a decrease in TSH values of all sera. The 
TSH values of PEG treated samples ranges from 0.69 to 90.5 with mean of 
13.78 and SD 16.96. TSH treated with deionised water used as a control ranges 
from 1.28 to 98.7 with mean of 20.65 and SD of  21.79.  
The present study showed that among 200 serum samples collected, with 
TSH more than 10 mU/L and FT4 within normal limits, 9 [ 4.5%] exhibited 
PEG-precipitable TSH ratios less than 25% recovery. This finding was 
consistent with the study done by Francesca Mills et al, which showed a similar 
result. Out of 9 serum sample, 4 [2%] of them showed a remarkable decrease in 
TSH recovery after protein G addition test . 
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In the study conducted by Francesca Mills et al., 
5
 low recovery 
percentage after PEG precipitation test < 25 % was detected in 15 (3 %) out of 
495 serum sample with TSH measurement more than 10 mU/L and macro TSH 
were identified in 3 of 15 serum samples by gel filtration chromatography. Gel 
filtration chromatography test is the suggested test for the diagnosis of macro-
TSH.  But the test could not be performed  because of the cumbersome 
procedure and cost. However, gel filtration chromatography may sometime do 
not differentiate the causes of interference  
76
 due to cross linking mechanism 
[eg heterophile antibodies] . Hence additional work to prove macroTSH like 
preincubation with urea, using acid elution buffer or selective precipitation 
with protein A or G sepharose is also proposed.  
Hiroyuki sakai et al 
7
 suggested protein G addition test for identification 
of macro TSH. In study conducted by Hiroyuki sakai et al 
7
 sample with 
recovery of 31% by protein G addition test suggested the presence of 
macroTSH. In the present study 4 patients showed a remarkable decrease in 
recovery % with protein G addition test in consistence with the study 
performed by hiroyuki sakai et al. The remarkable  decrease in TSH recovery 
after protein G addition test suggested that most of the TSH complex were 
removed by protein G agarose gel which mainly absorbs Ig G. Therefore most 
of the TSH existed in the form of macro TSH which is an immune complex of 
anti -TSH auto antibody mostly in the form of IgG and TSH. 
7 
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SUMMARY 
        The study of evaluation of immunoglobulin G complexed form of thyroid 
stimulating hormone [macro TSH] as interference in TSH assay was conducted 
in our  tertiary care hospital. 
200 serum samples were collected with TSH value more than 10 µIU 
/mL and FT4  within normal range [0.8 -2.7ng/dl]. Each serum sample were 
taken in two aliquots. Of all 200 samples were treated with PEG , serum 
samples with recovery less than 25% recovery were further subjected to protein 
G addition test. 
Among 200 serum samples, with TSH more than 10 mU/L and FT4 
within normal limits, 9 samples exhibited PEG-precipitable TSH ratios less 
than 25% recovery and were subjected to protein G addition test . Out of 9 
serum sample 4 [2%] sample showed remarkable decrease in TSH recovery 
after protein G addition test suggesting most of the TSH in those samples exist 
in the form of macro TSH which were  mostly IgG bound. 
To conclude it is important that clinical biochemists are aware of 
possible causes of immunoglobulin interference in TSH assays, including the 
90 
 
presence of macro-TSH, to prevent inappropriate interpretation of thyroid 
function test results from inﬂuencing clinical care. 
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CONCLUSION 
 
From the result of our study, we conclude that, Macro TSH mostly 
occurs in the form of TSH complexed with IgG .   9 (4.5%) serum samples with 
recovery less than 25 % with PEG were further subjected to protein G addition 
test 4 (2%) samples with remarkable decrease in TSH recovery after protein G 
addition test suggesting to have macro TSH. The clinician and laboratory 
personnel  should be aware of macro TSH as one of the cause of false elevation 
of TSH. Macro TSH should be suspected as one of the cause of interference 
when there is discordance between TSH level and the clinical features of the 
patient. Because macro TSH exhibited low bioactivity, thyroid hormone 
replacement therapy may not be required in patients with macro TSH.  PEG 
precipitation, which is a simple and cheap method, can be used as a screening 
test and samples with recovery less than 25 % should be confirmed further. Gel 
filtration chromatography is gold standard method for confirmation of macro 
TSH. As it is expensive , cumbersome for routine analysis and also fails to 
differentiate interferences 
5
 caused by cross linking mechanism [eg heterophile 
antibodies] , protein G addition test was used. 
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FUTURE PERSPECTIVE: 
The findings of this study are only suggestive. A larger sample size and 
further  confirmation of serum samples with gel filtration chromatography can 
be done to arrive at definite conclusion. 
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MASTER CHART 
s.no age  sex 
TSH 
µIU/mL 
FT4 
ng/dl TSH.PEG TSH.H2O  
% PEG 
recovery IgG .TSH 
IgG  
recovery% 
1 35 F 14.5 1.1 2.5 7.1 35.3 
  2 34 F 16.3 1.3 3.08 8.2 37.5 
  3 55 F 13.8 1.1 4.16 6.1 67.2 
  4 53 F 90.7 0.8 20.7 40.3 51 
  5 50 F 39.1 1.2 41 41.3 99 
  6 22 F 14.2 1.2 5.5 7.2 76 
  7 35 F 62.3 0.8 12.1 30.2 40 
  8 39 F 95 0.8 32.1 56 57 
  9 31 M 96 0.8 23 53 43 
  10 40 F 11.4 1 1.5 2.7 55 
  11 28 F 15.9 1.1 3.1 6.7 46.2 
  12 30 F 11.7 1.5 1.3 2.2 58 
  13 49 f 14.5 1.1 2.2 5.3 41 
  14 29 f 10.9 1.2 2.1 4.3 48 
  15 33 F 33.7 1 8.2 10.5 78 
  16 30 F 11.4 1.4 2.5 2.8 89 
  17 29 F 98 0.8 23.1 52 44 
  18 48 F 16.1 1.1 3.08 7.4 41.5 
  19 23 F 15.9 1 6.1 7.2 84.7 
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20 48 F 12.2 1.3 2.8 4.3 65.1 
  21 40 F 18.5 1.1 5.8 9.3 62.3 
  22 40 F 24.5 0.8 6.6 8.6 76.7 
  23 48 F 10.6 0.9 3.7 5.2 71.1 
  24 29 F 58.1 1.6 12.3 17.3 71.09 
  25 37 F 31.6 1 3.4 16.3 20.7 7.6 47% 
26 56 F 10.5 1 1.17 6.5 18 2.1 32% 
27 40 f 12.6 1 4.1 6.2 66.1 
  28 40 F 18.5 1.1 1.9 9.6 19.7 4.03 42% 
29 30 F 14.5 0.9 5.2 7.2 72.2 
  30 10 F 11.4 1 4.2 6.7 62.6 
  31 27 F 53.6 0.9 16.4 21.1 77.7 
  32 50 F 76.6 0.9 4.7 33.3 14.2 6.3 19% 
33 35 F 94 0.8 25.8 51.1 50.4 
  34 24 F 97 0.8 12.01 17.3 69.4 
  35 29 F 12.5 0.9 4.1 6.2 66.1 
  36 40 F 13.2 1.16 31.2 35.8 87.1 
  37 25 F 15.4 1.08 4.1 6.1 67.2 
  38 27 F 32.9 0.9 10.5 17.5 60 
  39 26 F 16.8 1.1 3.1 7.1 43.6 
  40 40 F 13.2 1.16 3.3 8.9 37.07 
  41 57 F 43.1 0.8 18.3 20.3 90 
  42 35 F 14.2 0.9 3.8 4.05 93.8 
  43 34 F 17.6 1.01 5.1 7.8 65.3 
  44 30 M 98 0.8 42.2 58.6 72.01 
  45 51 M 30.6 1.6 6.2 15.7 39.4 
  46 50 F 17.1 0.9 7.1 8.5 83.5 
  47 27 F 27.2 0.8 10.5 18.5 56.7 
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48 28 F 14.4 1.02 4.09 7.5 54.5 
  49 48 F 13.1 0.9 2.6 5.5 47.2 
  50 29 F 93 0.8 45.2 50.1 90.2 
  51 5 F 15.5 2.4 3.5 5.3 66 
  52 35 F 10.9 1.08 4.5 5.7 78.9 
  53 27 F 27.2 0.8 7.12 10.4 68.4 
  54 34 F 28.5 1 10.1 16.7 60.4 
  55 34 F 28.5 1 10.1 15 67.3 
  56 30 F 20.8 0.8 9 10.5 85.7 
  57 50 F 17.1 0.9 4.1 6.7 61.1 
  58 31 F 23.1 0.8 6.7 12.4 54.03 
  59 38 F 34.4 1.1 9.1 18.2 50 
  60 30 F 13.4 1 4.9 8.9 55 
  61 50 F 13.7 0.9 3.1 6.2 50 
  62 57 F 11.02 1.14 3.2 4.9 65.3 
  63 30 F 13.6 0.9 4.6 5.3 86.7 
  64 26 F 21.6 0.8 14.6 21.1 69.1 
  65 33 F 15.6 0.9 5.9 8.4 70.2 
  66 55 F   26.3 0.8 10.8 11.7 92 
  67 44 F 77.6 0.8 9.6 18.4 52.1 
  68 45 F 10.2 0.8 1.8 2.6 69 
  69 42 F 96 0.8 41 52 78 
  70 55 F 26.3 0.8 8.1 14.1 57 
  71 44 F 77.6 0.8 9.6 18.4 52.1 
  72 45 F 10.2 0.8 1.8 2.6 69.2 
  73 42 F 94 0.8 41.1 52 79 
  74 56 M 26.1 1.1 8.1 14 57.8 
  75 50 F 39.4 0.8 18.2 20.1 90.5 
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76 30 F 16.4 0.8 7.3 8.2 89.02 
  77 55 F 12.7 0.8 4.4 6.3 69.8 
  78 15 F 92 0.8 40.2 51.6 77.9 
  79 49 M 14.5 0.8 5.1 7.2 70.8 
  80 63 F 14.4 0.8 4.2 7.5 56 
  81 29 M 12.8 0.8 3.1 6.5 47 
  82 45 M 44.5 0.9 10 20.1 49.7 
  83 40 F 91 0.8 25.7 51.1 50.2 
  84 32 F 62.2 0.8 2.8 31.3 8.9 5.01 16 
85 32 F 28.6 0.8 7.9 13.7 57.6 
  86 54 M 14.9 1.08 2.5 5.08 49 
  87 34 M 13.5 0.9 2.7 8.86 30.6 
  88 34 M 29 0.9 9.01 18.15 49.5 
  89 52 F 10.8 1.2 3.3 5 66 
  90 47 F 74.1 0.8 32.7 41.5 78 
  91 45 F 97 0.8 58.4 83.2 70.1 
  92 67 F 35.9 0.8 14.7 22.6 65 
  93 40 F 10.2 0.8 4.18 6.1 67 
  94 10 F 96 0.8 20.1 48.6 41 
  95 45 F 18.7 1.2 4.2 8.5 48 
  96 23 F 75.9 0.9 20 35 57 
  97 37 F 14.5 1.2 7.2 8.7 82 
  98 22 F 98 0.8 37.3 48 77 
  99 44 F 57.9 0.8 20.7 25 82 
  100 35 F 11.7 0.8 4.1 5.5 74 
  101 57 M 11.2 0.9 5.5 6.1 90 
  102 55 F 18.8 1.1 8.1 10 81 
  103 45 F 31.8 0.8 14.1 15.2 92 
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104 37 F 11.2 0.9 4.1 5.5 74 
  105 40 F 61.4 0.8 20.7 30.1 68 
  106 32 F 81.9 0.8 45 46.1 97 
  107 40 F 15.9 1.1 4.3 8.5 50 
  108 41 F 15.9 0.9 7.4 8.5 87 
  109 40 F 76.6 0.8 30 35.1 85 
  110 30 M 12.4 0.9 5.8 6.1 95 
  111 60 F 73 0.9 23.7 31.2 75.9 
  112 51 M 19.4 0.9 7.1 10.7 63.3 
  113 30 F 16.2 1.04 5.3 8.1 65.4 
  114 40 M 14.2 1 6.1 7.4 82.4 
  115 40 M 25.1 1 11.3 12.6 89.6 
  116 50 F 39.4 0.8 9.8 19.5 50.2 
  117 60 M 11.2 0.9 3.1 5.1 60 
  118 47 F 13.1 0.9 4.3 6.3 68.2 
  119 43 F 25.1 1.2 9.04 12.1 74.7 
  120 5 F 15.5 1.4 5.8 7.4 78.3 
  121 37 F 44.5 0.8 33.6 44.8 75 
  122 22 F 64.6 0.8 48.8 66.9 72 
  123 22 F 95 0.8 87.17 98.1 88 
  124 29 F 98 0.8 86.7 98.4 88 
  125 24 F 10.4 1.4 5.2 8.9 58.4 
  126 37 F 32.9 0.8 17.13 26.1 65 
  127 36 F 37.8 0.8 16.8 18.8 89 
  128 35 F 99 0.8 63.3 98.6 64 
  129 34 F 98 0.8 9.8 28.02 34 
  130 22 F 11.8 0.9 0.69 1.28 53 
  131 36 F 14.9 0.8 9.4 10.4 90.3 
  
111 
 
132 37 F 10.9 1 5.7 9.9 57.5 
  133 27 F 10.4 1.2 4.8 5.9 81.3 
  134 37 F 22.4 0.8 4.6 12.5 36.8 
  135 34 F 14.4 1.5 1.8 4.3 41.8 
  136 32 F 17.4 0.9 2.3 4.7 48.9 
  137 28 F 12.6 1.1 1.15 6.8 17 1.7 25% 
138 27 F 35.9 0.8 8.49 22.18 38 
  139 37 F 98.6 0.8 23.9 26.12 91.5 
  140 17 F 10.6 0.9 2.6 3.03 85.8 
  141 37 F 22.6 1.2 14.5 26.8 54.1 
  142 32 F 42.9 0.8 14.7 33.9 43.6 
  143 27 F 97.6 0.8 68.01 85.5 79.5 
  144 65 M 97.7 0.8 24.09 35.1 68.6 
  145 31 F 37.1 0.8 12.06 16.02 75.2 
  146 36 F 98.8 0.8 90.5 92 98.9 
  147 38 F 14.8 0.8 8.15 8.6 94 
  148 28 F 91 0.8 53.9 98.7 54.6 
  149 58 F 39 0.8 18.1 26.2 69 
  150 45 F 15.9 1 8.02 12.6 63.6 
  151 44 F 98 0.8 60.5 80.1 76.02 
  152 39 F 96 0.9 51.2 60.7 84.3 
  153 42 F 23.3 1 9.5 13.2 71 
  154 35 F 65.4 0.8 12.8 14.4 88.8 
  155 20 M 10.5 0.9 6.03 6.9 87 
  156 50 F 20.2 1.1 2.9 4.1 70.7 
  157 51 F 13.6 0.8 6.6 11.7 56.4 
  158 50 M 31.4 0.8 12.4 15.2 81.5 
  159 13 F 98 0.9 18.7 24.8 75.4 
  
112 
 
160 50 F 99.2 0.8 40.3 52.2 77.2 
  161 29 F 76.1 1 2.2 7.05 31.2 
  162 30 F 35 0.8 7.6 14.9 51 
  163 27 F 16.5 0.8 1.7 2.7 62.9 
  164 43 F 17.9 1.5 2.3 3.4 67.6 
  165 31 F 21.5 0.9 4.6 7.9 58.2 
  166 34 F 42.7 1.1 13.7 20.5 66.8 
  167 40 F 12.8 1.5 3.5 8.9 39.3 
  168 21 F 12 1.1 6.2 15.6 39.7 
  169 45 F 12.8 1.1 1.02 6.4 16 1.34 20% 
170 22 F 14.7 1.4 2.4 5.7 42.1 
  171 55 F 28.1 1.6 3.12 14.2 22 6.8 48.00% 
172 14 M 94 0.9 44.3 61.9 71.5 
  173 20 M 11.1 1 1.5 3.14 47.7 
  174 25 F 13.7 1.3 1.1 3.6 30.5 
  175 35 F 16.2 1.3 3.2 3.6 88.8 
  176 56 M 38.7 0.9 4.6 11.06 41.5 
  177 30 F 21.8 0.9 6.19 18.08 34.2 
  178 32 F 11.9 1.6 0.89 5.13 17.3 1.8 35.00% 
179 39 F 30.3 1.4 38.4 60.17 63.8 
  180 50 f 13.6 1 1.5 5.2 28.8 
  181 39 F 30.3 1.4 38.4 60.17 63.8 
  182 35 F 98.7 0.9 43.5 66.1 65.8 
  183 55 F 61.5 0.9 15.7 30.2 51.9 
  184 45 F 28.7 0.9 9.9 31.08 31.8 
  185 32 F 10.1 0.9 1.9 4.2 45.2 
  186 22 F 25.7 1 8.09 12.3 65.7 
  187 46 F 17.7 0.8 5.7 8.4 67.8 
  
113 
 
188 56 F 12 1 2.1 4.2 50 
  189 38 F 40.5 0.9 8.4 13.9 60.4 
  190 63 F 23.4 0.9 5.3 10.8 49.07 
  191 6 F 10.5 1 1.8 2.4 75 
  192 60 F 97 0.8 48 59 81.3 
  193 32 F 23.4 0.8 8.4 13.3 63.1 
  194 45 F 11.5 0.8 2.9 6.7 43.2 
  195 18 F 16.1 0.9 6.3 11.2 56.2 
  196 50 F 97 0.9 50.1 56.6 88.5 
  197 33 F 12.1 0.8 2.4 3.1 77.4 
  198 35 F 18.4 1 6.8 12.4 54.8 
  199 40 F 18.6 0.8 4.4 6.07 72.4 
  200 25 F 72.9 0.9 28.1 48.5 57.9 
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